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Abstract
Methylphenidate (MPH) is widely prescribed for adults with attention deﬁcit hyperactivity disorder
(ADHD), but data on long-term treatment and maintenance of eﬀect are lacking. Osmotic release oral
system-methylphenidate (OROS–MPH) was evaluated in a 52-wk open-label study in subjects who had
previously completed a short-term placebo-controlled trial and short-term open-label extension. Eﬃcacy
was assessed using the investigator- and subject-rated Conners’ Adult ADHD Rating Scales (CAARS:O-
SV and CAARS:S-S), and the Clinical Global Impression – Severity (CGI-S), Sheehan Disability Scale (SDS)
and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Subjects completing i52 wk of
treatment were eligible for a 4-wk randomized, placebo-controlled withdrawal phase in which loss of
treatment eﬀect was assessed using CAARS:O-SV and CGI-S. In the open-label phase (n=156), mean
CAARS:O-SV score decreased from baseline by 1.9¡7.8 (p<0.01), and small, statistically signiﬁcant im-
provements from baseline were observed for CAARS:S-S, CGI-S and SDS. In the double-blind phase
(OROS-MPH, n=23; placebo, n=22), CAARS:O-SV increased from double-blind baseline in the OROS-
MPH and placebo arms (4.0¡7.6 vs. 6.5¡7.8, not statistically signiﬁcant). Long-term OROS-MPH treat-
ment was well tolerated, and there was no evidence of withdrawal or rebound after discontinuation. In
conclusion, the short-term beneﬁts of OROS-MPH continue during long-term open-label treatment.
Maintenance of eﬃcacy in a placebo-controlled withdrawal design remains to be conﬁrmed in larger
patient populations.
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Introduction
Attention deﬁcit hyperactivity disorder (ADHD) per-
sists into adulthood as a chronic neurobehavioural
disorder in a substantial number of persons diagnosed
in childhood (Faraone et al. 2006). Based on national
and international guidelines as well as consensus
statements, the treatment of choice for adults with
ADHD is methylphenidate (MPH) (Kooij et al. 2010;
National Collaborating Centre for Mental Health,
2009; Social and Health Directory, 2010). The eﬃcacy
and safety of both short- and long-acting MPH have
been demonstrated in numerous clinical trials in
adults with ADHD in the USA (Adler et al. 2009;
Biederman et al. 2010; Spencer et al. 2005) and in
Europe (Bouﬀard et al. 2003; Kooij et al. 2004; Medori
et al. 2008). In a previous study with osmotic release
oral system-methylphenidate (OROS-MPH) (the
LAMDA trial), treatment was associated with signiﬁ-
cant improvement in core symptoms of ADHD
[Conners’ Adult ADHD Rating Scale (CAARS)] rela-
tive to placebo, as well as improvements in daily
functioning and global condition (Medori et al. 2008).
These beneﬁts were maintained or further improved
in a 7-wk open-label extension (Buitelaar et al. 2009).
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Attention-Deficit Hyperactivity
Disorder (ADHD)Data on outcomes of MPH treatment beyond 6 months
in adults with ADHD are, however, limited (Bejerot
et al. 2010; Wender et al. 2011).
Data in the literature are also limited regarding the
maintenance of eﬀect of long-term medication, par-
ticularly in adults. A randomized, placebo-controlled
withdrawal study of atomoxetine that included two
discontinuations of medication has been conducted
in children and adolescents (Buitelaar et al. 2007;
Michelson et al. 2004). After 12 wk of stabilization
treatment, relapse – deﬁned as a return to 90% of
baseline severity – occurred in 22% and 38% of
atomoxetine- and placebo-treated subjects, respect-
ively, during 9 months of continuation or withdrawal
(Michelson et al. 2004). In the second randomized dis-
continuation phase, relapse rates after 12 months of
stabilization were 3% vs. 12% for atomoxetine-
and placebo-treated subjects, respectively, during
6monthsofcontinuation orwithdrawal(Buitelaaretal.
2007). Maintenance of eﬃcacy of OROS-MPH was
evaluated in a small double-blind, placebo-controlled,
4-wk withdrawal period in subjects who responded in
a preceding active medication period (Biederman et al.
2010). Of 23 subjects who had previously responded to
OROS-MPH in a 6-wk acute eﬃcacy trial followed
by 24 wk of maintenance treatment, two subjects
(18%) experienced relapse after switching to placebo
compared to no patient who continued OROS-MPH,
although the diﬀerence was not statistically signiﬁ-
cant.
To provide long-term safety, eﬃcacy, functioning
and quality-of-life data in adults receiving OROS-
MPH, subjects who completed the LAMDA trial were
enrolled in an open-label study of i52-wk duration.
Maintenanceofeﬀectwasevaluatedina4-wkrandom-
ized, double-blind, placebo-controlled withdrawal
phase in subjects who completed the present open-
label study.
Methods
Subjects
Subjects were adult men or women aged 18–65 yr with
a diagnosis of ADHD according to DSM-IV criteria.
Diagnosis was based on the Conners’ Adult ADHD
Diagnostic Interview for DSM-IV (CAADID; Conners
et al. 1999), which conﬁrms the chronic course of
ADHD symptomatology from childhood to adult-
hood, with some symptoms present before age 7 yr. In
addition, a CAARS total score (sum of Inattention and
Hyperactivity/Impulsivity scores) of i24 at screening
for the initial LAMDA study was required. The
Structured Clinical Interview for DSM-IV (SCID-I/P)
was used to evaluate the presence of other
comorbidities and exclusionary symptoms (see be-
low). ADHD was not diagnosed if symptoms were
better accounted for by another psychiatric disorder
(e.g. mood, anxiety, psychotic, personality disorder).
Key exclusion criteria were a history of poor response
or intolerance to MPH; presence of any current
clinically unstable psychiatric condition (e.g. acute
mood disorder, bipolar disorder, acute obsessive-
compulsive disorder); diagnosis of substance use
disorder (abuse/dependence) according to DSM-IV
criteria within the last 6 months. Other exclusion
criteria included family history of schizophrenia or
aﬀective psychosis; serious illnesses (e.g. hepatic or
renal insuﬃciency or signiﬁcant cardiac, gastroin-
testinal, psychiatric, or metabolic disturbances);
hyperthyroidism, myocardial infarction, or stroke
within 6 months of screening; and history of seizures,
glaucoma, or uncontrolled hypertension. In addition,
subjects with a treatment gap of >30 d after the end of
the 7-wk open-label extension of the LAMDA study
were not eligible for the present study.
Study design
The present study was completed in July 2008 and
was conducted in 23 of the 51 sites (7/13 European
countries) that participated in the LAMDA study.
Subjects who initially entered the 5-wk, double-
blind, randomized, placebo-controlled, parallel-
group, ﬁxed-dose LAMDA study (Medori et al. 2008)
were eligible for a 7-wk open-label, ﬂexible-dose ex-
tension if they completed the 5-wk double-blind phase
or discontinued study medication due to poor toler-
ability (after a minimum of 7 d of treatment in the
double-blind phase) (Buitelaar et al. 2009). Completers
of the 7-wk open-label phase (including those who
had received placebo in the initial 5-wk trial) were
eligible for the present open-label study. Subjects who
had at least 52 wk of treatment with OROS-MPH
were eligible for a 4-wk, randomized, double-blind,
placebo-controlled withdrawal phase if they had re-
ceived a stable OROS-MPH dose for 4 wk at the end of
the open-label study. Subjects in the withdrawal phase
were randomly assigned in a 1:1 ratio to one of two
groups receiving either continued treatment with the
same dose of OROS-MPH or placebo.
Written informed consent was obtained from all
patients before entering the open-label study, with
separate consent required to enter the double-blind
withdrawal phase. As a result, the timing of the open-
label phase discontinuation was known to the subjects
and investigators.
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immediately after LAMDA continued their previous
OROS-MPH dose. Subjects who experienced an inter-
ruption of study drug between the open-label phase of
LAMDA and the current study were titrated from
18 mg/d to a clinically optimal dose. Subjects were
maintained on a ﬂexible dose of OROS-MPH (18, 36,
54, 72 or 90 mg/d) throughout the open-label study.
The dosage could be increased or decreased by 18-mg
increments as needed to a maximum of 90 mg/d; dose
alterations were based on clinical observations of re-
sponse and tolerability and were made entirely at the
discretion of the investigator.
This study was conducted in accordance with the
ethical principles that have their origin in the Declar-
ation of Helsinki and that are consistent with Good
Clinical Practice (GCP) and applicable regulatory re-
quirements. The study protocol was approved by in-
dependent ethics committees at each participating site.
Assessments
ADHD symptoms were evaluated using CAARS.
The primary assessment in each study phase was the
CAARS Observer-rated – Short Version (CAARS:
O-SV), which comprises 18 investigator-rated items
corresponding to the 18 DSM-IV-deﬁned ADHD
symptoms and provides a total score referred to as
the CAARS:O-SV total ADHD symptom score and
two subscale scores (Inattention and Hyperactivity/
Impulsivity) (Conners et al. 1999). The CAARS
Self-rated Short Version (CAARS:S-S) is a 26-item,
self-report, 4-point rating scale that measures symp-
toms based on DSM-IV criteria for ADHD (Conners
et al. 1999). Investigators who performed CAARS as-
sessments successfully completed a formal training
and qualiﬁcation programme organized by the study
sponsor. Other outcome measures included the
7-point Clinical Global Impression – Severity (CGI-S)
and Change (CGI-C) scales, the former rating the de-
gree of illness from 1 (not ill) to 7 (extremely severe),
and the latter rating the level of improvement relative
to baseline from 1 (very much improved) to 7 (very
much worse) (NIMH, 1985). Functional impairment
was assessed using the Sheehan Disability Scale (SDS),
designed to measure impairment in three domains
(work, social and home life or family responsibilities)
with a self-administered 10-point visual analogue
scale (Sheehan et al. 1996). Quality of life was
measured using the 14-item Quality of Life Enjoyment
and Satisfaction Questionnaire – Short Form (Q-LES-
Q), which evaluates the level of enjoyment and satis-
faction relating to physical health, feelings, work,
household duties, work and leisure-time activities,
and social relations. Each domain is assessed on a
5-point scale from very poor to very good, and the
domains are aggregated to produce an overall score
(Endicott et al. 1993). The instrument is not disease-
speciﬁc and has been used in a number of clinical
trials, including clinical trials in adults with ADHD,
and sensitivity to treatment eﬀects with MPH has been
demonstrated (Mick et al. 2008). Safety evaluations
included monitoring of adverse events, clinical lab-
oratory tests, vital signs, and physical examination.
Electrocardiogram (ECG) recordings were made in a
subset of subjects.
During the present open-label study, clinic visits
were carried out every 12 wk, with safety parameters
and adverse events assessed at each visit. Eﬃcacy as-
sessments were carried out at baseline and endpoint,
except in Germany, where CAARS:O-SV, CAARS-
S:SV and CGI-S scores were also evaluated every
12 wk. In the double-blind withdrawal phase, safety
and eﬃcacy assessments were carried out at baseline
and endpoint (4 wk), with an additional assessment of
safety and CAARS:O-SV score at week 2. ‘Baseline’
was deﬁned as the ﬁrst visit of the present study; for
patients who continued into the open-label study
immediately after completing LAMDA, the end-of-
study visit in LAMDA could serve as the baseline visit
for the present study.
Statistical analysis
Safety and eﬃcacy were evaluated in the intent-to-
treat (ITT) population, deﬁned for the open-label and
double-blind phases as all subjects who received at
least one dose of study medication in the respective
phase.
In the open-label phase, adverse events were sum-
marized, including data on severity and outcome of
treatment-emergent adverse events of special interest
(protocol-speciﬁed cardiovascular and psychiatric ad-
verse events), and summary statistics were generated
for cardiovascular parameters and eﬃcacy data.
Sample size for the double-blind phase was based
on a conservatively expected change in CAARS:O-SV
total score from double-blind baseline of +3 for con-
tinued MPH and +10 for placebo over a 4-wk period,
based on clinical assessment. With a two-sided type-I
error of 5% and a power of 90%, 37 eligible subjects
per treatment group were required. It was therefore
planned to enrol a total of 80 subjects into the double-
blind withdrawal phase. During the double-blind
phase, the primary and, where appropriate, secondary
eﬃcacy variables were analysed at each time-point
Long-term OROS-MPH treatment in adults with ADHD 3(2 and 4 wk) and at endpoint by analysis of covariance
(ANCOVA), including treatment, country, age and sex
as factors, and baseline score as a covariate. Treatment
eﬀects were estimated based on least-squares means of
the diﬀerence between the continued treatment group
and placebo.
Additional pre-speciﬁed analyses to evaluate loss of
therapeutic eﬀect in the double-blind phase included
the percentage of subjects with a i1-point increase
in CGI-S score from double-blind baseline and the
percentage of subjects with a i2-point increase in
CGI-S score from double-blind baseline or discon-
tinuation because of lack of eﬃcacy during the double-
blind period.
Post-hoc analyses performed to evaluate possible
rebound eﬀects during the placebo-controlled with-
drawal period were based on mean change from
open-label baseline in CAARS:O-SV total score and
percentage of subjects with a i1-point increase in
CGI-S score from open-label baseline at double-blind
endpoint.
Adverse events in the open-label phase were sum-
marized and summary statistics were generated for
cardiovascular parameters and eﬃcacy data. For
the evaluation of possible withdrawal symptoms,
adverse events were assessed from the beginning of
the double-blind withdrawal phase to the last post-
baseline visit in the double-blind period.
Results
Open-label phase
Of 337 subjects who completed the LAMDA trial, 156
were screened for the present open-label study; the
most common reason for not entering screening was
that the subject’s country or individual study site did
not participate (n=121). One patient did not meet
the inclusion criteria, and thus 155 subjects entered
the open-label study (Fig. 1). Baseline demographics
and disease characteristics are shown in Table 1.
Median age at baseline was 36 yr and 54% of patients
were male. Median age at diagnosis of ADHD was
33 yr and most patients had combined-type ADHD
(68%). A family history of ADHD was present in
74% of patients, and 36% had a family history of
other psychiatric disorders. As per the inclusion and
exclusion criteria, few patients had active, stable
Screened for open-label
study (n=156)
Entered open-label phase
(n=155)
Screening failure (n=1)
Withdrawals (n=56)
• Adverse event (n=16)a
• Withdrew consent (n=15)
• Lost to follow-up (n=11)
• Non-compliance (n=5)
• Lack of efficacy (n=3)
• Other (n=6)
Completed open-label phase
(n=99)
Entered double-blind phase
(n=45)
Did not enter
double-blind phase (n=54)
PR OROS MPH (n=22) Placebo (n=23)
Withdrawals (n=2) 
• Lack of efficacy (n=2)
Withdrawals (n=5) 
• Lack of efficacy (n=5)
Completed double-blind phase (n=17) Completed double-blind phase (n=20)
Fig. 1. Patient disposition in the open-label and double-blind phases of the study. a Includes one patient who discontinued
because of an adverse event that began before entry into the present study. PR, Prolonged release.
4 J. K. Buitelaar et al.psychiatric comorbidities at baseline [alcohol/
substance abuse: n=1 (1%); mood and anxiety dis-
orders: n=16 (10%); personality disorders: n=1
(1%)].
In total, 125 subjects (80.6%) were receiving at least
one concomitant medication at baseline. The most
frequently used medication classes were analgesics
(n=58, 37.4%), anti-inﬂammatory and anti-rheumatic
products (n=48, 31.0%) and systemic antibiotics
(n=32, 20.6%). Drugs classiﬁed as psychoanaleptics
(e.g. antidepressants) or psycholeptics (e.g. benzodi-
azepines and non-benzodiazepine hypnotics) were
each used by 20 subjects (12.9%).
Overall, 99 subjects (63.9%) completed the open-
label phase. The main reasons for trial discontinuation
during the open-label phase were the occurrence of an
adverse event (n=16, 10.3%), withdrawal of consent
(n=15, 9.7%) and loss to follow-up (n=11, 7.1%).
Mean (¡S.D.) treatment duration in the open-label
phase (safety population) was 437.1¡206.8 d (median
503.0 d, range 15–747 d). The mean daily dose of
OROS-MPH was 52.8¡21.0 mg (median 53.9 mg,
range 18–90 mg). The most frequent modal daily doses
were 36 mg (33.3%) and 54 mg (24.2%), with 7.2, 18.2
and 16.3% of patients receiving a modal dose of 18, 72
or 90 mg, respectively.
Safety
In total, 126 subjects (81.3%) experienced at least one
treatment-emergent adverse event during the open-
label study (Table 2). The most common treatment-
related adverse events were restlessness, headache
and drug eﬀect decreased, each in nine subjects
(5.6%). Seventeen serious adverse events were re-
ported in 12 (7.7%) subjects, comprising one case each
of hip arthroplasty, hip surgery, lipoma excision,
mastectomy, tonsillectomy, recurrent breast cancer,
uterine leiomyoma, menorrhagia, uterine haemor-
rhage, deafness, haemorrhoids, allergy to arthropod
sting, concussion, whiplash injury, investigation (re-
ported term: ‘diagnostic curettage’), intervertebral
disc protrusion, and thrombosis. None was considered
by the investigator to be related to treatment. No
deaths were reported during the study. Fifteen (9.7%)
subjects withdrew from the study because of an ad-
verse event, with one additional patient withdrawing
because of an adverse event that had begun before
entering the open-label study. Adverse events leading
to withdrawal in more than one patient were insom-
nia, depressed mood, and hypertension (all n=2,
1.3%). Treatment-emergent adverse events of special
interest reported by more than one patient were
Table 1. Demographic and disease characteristics at the start of the open-label and double-blind phases
Open-label
Double-blind
OROS-MPH (n=155) Placebo (n=22) OROS-MPH (n=23)
Age, yr
Mean¡S.D. 35.0¡10.6 35.1¡9.8 37.5¡12.0
Range 18–60 20–52 21–62
Sex, n (%)
Male 84 (54.2) 7 (31.8) 11 (47.8)
Female 71 (45.8) 15 (68.2) 12 (52.2)
Age at ADHD diagnosis
Mean¡S.D. 30.1¡14.4 26.4¡15.3 28.1¡17.4
Range 3–60 4–49 4–60
ADHD subtype (childhood, based on CAADID), n (%)
Combined 114 (73.5) 13 (59.1) 16 (69.6)
Predominantly inattentive 35 (22.6) 8 (36.4) 5 (21.7)
Predominantly hyperactive-impulsive 5 (3.2) 1 (4.5) 2 (8.7)
Not speciﬁed 1 (0.6) 0 0
ADHD subtype (adulthood), n (%)
Combined 106 (68.4) 12 (54.5) 12 (52.2)
Predominantly inattentive 43 (27.7) 10 (45.5) 8 (34.8)
Predominantly hyperactive-impulsive 5 (3.2) 0 3 (13.0)
Not speciﬁed 1 (0.6) 0 0
CAADID, Conners’ Adult ADHD Diagnostic Interview for DSM-IV.
Long-term OROS-MPH treatment in adults with ADHD 5hypertension (n=9, 5.8%), palpitations (n=6, 3.9%)
and anxiety (n=4, 2.6%). Except for one patient with
palpitations categorized as severe and one patient
with anxiety categorized as severe, adverse events of
interest were mild to moderate in severity, and none
was classiﬁed as serious.
Mean changes from baseline in blood pressure
and pulse rate during the open-label study were small
(Table 3). Abnormally high systolic (>140 mmHg) and
diastolic (>90 mmHg) blood pressure values at any
post-baseline visit during the open-label phase were
reported in 21.7% and 17.1% of subjects, respectively,
with 9.2% of subjects recording a pulse rate >100 bpm
(Table 3). Body weight and body mass index (BMI) re-
mainedstablethroughoutthestudy,withmean(¡S.D.)
changes of 0.7¡4.8 and 0.23¡1.61 kg, respectively.
Eﬃcacy
CAARS:O-SV total score slightly improved (de-
creased) throughout the open-label phase, and was
signiﬁcantly lower at endpoint vs. baseline [last ob-
servation carried forward (LOCF) analysis; Fig. 2;
Table 4]. Signiﬁcant improvements from baseline
were also seen in the CAARS:O-SV Hyperactivity/
Impulsivity and Inattention subscale scores,
CAARS:S-S score, CGI-S, and SDS scores. No signiﬁ-
cant change in Q-LES-Q was reported (LOCF analysis)
(Table 4). The percentage of subjects categorized as
‘not ill’, ‘borderline ill’, or ‘mildly ill’ on the CGI-S
increased from 69.0% at baseline to 75.5% at endpoint
(Fig. 3).
Double-blind phase
Of 99 subjects who completed the open-label study, 45
(45%) consented to enter the double-blind phase, of
Table 2. Summary of adverse events occurring during the open-label phase
Adverse event, n (%) OROS-MPH (n=155)
Any adverse event 126 (81.3)
Discontinued because of adverse event 15 (9.7)a
Serious adverse event 12 (7.7)
Treatment-related adverse eventb 62 (40.0)
Most common adverse events (i5% of subjects)
Headache 33 (21.3)
Nasopharyngitis 31 (20.0)
Inﬂuenza 10 (6.5)
Restlessness 12 (7.7)
Back pain 11 (7.1)
Insomnia 11 (7.1)
Drug eﬀect decreased 9 (5.8)
Hypertension 9 (5.8)
Depressed mood 8 (5.2)
aOne additional patient discontinued because of an adverse event that began before
entry into the present study.
bAdverse event considered by the investigator to be possibly, probably or very likely
to be related to study medication.
Table 3. Cardiovascular parameters during the open-label
phase
Parameter (mean¡S.D.)
OROS-MPH
(n=155)
Systolic blood pressure (mmHg)
Baseline 123.0¡13.2
Endpoint 123.5¡12.6
Change 0.3¡14.0
Diastolic blood pressure (mmHg)
Baseline 75.7¡8.4
Endpoint 77.1¡10.2
Change 1.4¡9.7
Pulse rate (bpm)
Baseline 76.9¡13.3
Endpoint 77.8¡11.7
Change 0.9¡14.4
Subjects meeting clinically relevant criteria at any visit, n (%)
Systolic blood pressure >140 mmHg 33 (21.7)
Diastolic blood pressure >90 mmHg 26 (17.1)
Pulse rate >100 bpm 14 (9.2)
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(11%) randomized to placebo withdrew because of
lack of eﬃcacy (Fig. 1). Demographic and disease
characteristics at double-blind baseline were generally
similar in the placebo and OROS-MPH arms, and were
also similar to those at open-label baseline (Table 1).
There was, however, an apparent imbalance in
CAARS:O-SV score between the placebo (12.1¡5.3)
and OROS-MPH (16.5¡7.5) arms.
Mean doses of OROS-MPH or placebo equivalent
during the double-blind phase were 43.0¡16.9 mg
[median (range), 36 (18–72) mg] and 54.8¡23.9 mg
[54 (18–90) mg], respectively.
Eﬃcacy
Mean CAARS:O-SV total score increased from
double-blind baseline in both treatment arms, with no
signiﬁcant diﬀerence for change from baseline be-
tween placebo and OROS-MPH (Fig. 4; Table 5). Six
(26.1%) subjects in the OROS-MPH arm and eight
(36.4%) in the placebo arm experienced an increase
(worsening) of >50% from baseline in CAARS:O-SV
total score, while 13 subjects (56.5%) and 10 subjects
(45.5%), respectively, experienced an increase of
<30% in CAARS total score.
CGI-C scores indicated statistically signiﬁcantly less
worsening of symptoms at double-blind endpoint
compared to double-blind baseline in the OROS-MPH
arm [median (range) 4.0 (1–6)] than in the placebo
arm [5.0 (2–7)]. At endpoint, the percentages of sub-
jects who were considered minimally to very much
worse relative to baseline were 30.4 and 59.1% in
the OROS-MPH and placebo arms, respectively
(p=0.0422) (Fig. 5). No patient in the OROS-MPH
arm was considered to be ‘very much worse’. At
double-blind endpoint, the percentage of subjects
rated as moderately, markedly, or severely ill on the
CGI-S was 59.1% in the placebo group and 30.4% in
the OROS-MPH group (compared to 13.6% and 0%,
respectively, at double-blind baseline). No signiﬁcant
diﬀerences in secondary eﬃcacy parameters other
than CGI-C were observed between the treatment
arms, although there was a consistent trend to nu-
merically better outcomes with OROS-MPH (Table 5).
Loss of treatment eﬀect and rebound
Loss of treatment eﬀect during double-blind treat-
ment, in terms of increases from double-blind baseline
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Fig. 2. Conners’ Adult ADHD Rating Scale Observer-
rated – Short Version (CAARS:O-SV) total score during the
open-label phase.
Table 4. Eﬃcacy parameters during the open-label phase
(LOCF analysis)
Parametera (mean¡S.D.) OROS-MPH (n=155)
CAARS:O-SV total score
Baseline 18.9¡8.3
Endpoint 17.0¡8.3
Change x1.9¡7.8**
CAARS:O-SV hyperactivity/impulsivity subscale
Baseline 8.8¡4.4
Endpoint 7.9¡4.6
Change x0.9¡4.4**
CAARS:O-SV inattention subscale
Baseline 10.1¡5.1
Endpoint 9.1¡5.0
Change x1.0¡4.6**
CAARS-S:SV
Baseline 29.6¡13.1
Endpoint 26.5¡13.5
Change –3.1¡9.6***
Clinical Global Impression – Severity
Baseline 3.1¡1.0
Endpoint 2.8¡1.1
Change –0.3¡1.1**
Q-LES-Q
Baseline 60.0¡15.1
Endpoint 61.9¡16.6
Change 1.4¡15.2
Sheehan Disability Scale
Baseline 12.8¡6.6
Endpoint 11.1¡6.3
Change x1.7¡6.2***
CAARS, Conners’ Adult ADHD Rating Scale; CAARS:O-SV,
CAARS Observer-rated – Short Version; CAARS:S-SV,
CAARS Self-rated Short Version; Q-LES-Q, Quality of Life
Enjoyment and Satisfaction Questionnaire.
aA reduction in score represents an improvement for all
scales except Q-LES-Q.
** pj0.01, *** p<0.001 vs. baseline (two-sided paired t test).
Long-term OROS-MPH treatment in adults with ADHD 7in CGI-S score at double-blind endpoint, was observed
in more subjects in the placebo arm than in the OROS-
MPH arm, although the diﬀerences were not statisti-
cally signiﬁcant (Fig. 6).
Based on mean changes in CAARS:O-SV total score
from open-label baseline, subjects who received pla-
cebo were more likely to experience worsening of
ADHD symptoms at double-blind endpoint, while
those who continued OROS-MPH did not show a
change in ADHD symptoms in general (mean change
in CAARS:O-SV total score, 4.5 vs. x0.3, respectively).
A greater percentage of subjects randomized to pla-
cebo (55%) experienced an increase in CGI-S score of
i1 point from open-label baseline to double-blind
endpoint compared to those who continued treatment
with OROS-MPH (30%).
Safety
During double-blind treatment, 30.4% and 36.4% of
subjects in the OROS-MPH and placebo arms, re-
spectively, experienced at least one adverse event
(Table 6). No individual adverse event was reported
in more than two subjects per treatment group. The
only serious adverse event was a patient receiving
placebo diagnosed with recurrent breast cancer
who underwent mastectomy and reconstructive sur-
gery; this was not considered by the investigator to
be related to treatment. Adverse events considered
by the investigator to be at least possibly related to
treatment were reported in three subjects (13.0%) in
the OROS-MPH arm and ﬁve subjects (22.7%) in
the placebo arm. The only cardiovascular adverse
events of special interest were two cases of reported
hypertension in subjects receiving OROS-MPH, and
no psychiatric adverse events of special interest oc-
curred during the double-blind phase. There were no
adverse events suggestive of a withdrawal reaction in
subjects assigned to placebo during the double-blind
phase.
Mean blood pressure and pulse rate decreased
in subjects switched to placebo, with minimal
changes in subjects who continued OROS-MPH
(Table 7). Abnormally high diastolic blood pressure
(>90 mmHg) and pulse rate (>100 bpm) at any post-
baseline visit in the double-blind phase were each ex-
perienced by two subjects in the OROS-MPH arm.
Discussion
Results from this long-term open-label study show
that adults with ADHD receiving long-term treatment
with OROS-MPH continue to experience small but
statistically signiﬁcant improvement in their con-
dition. Improvements from baseline in the open-label
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8 J. K. Buitelaar et al.phase were observed for the level of ADHD symp-
toms, disease severity, and impairment of functioning,
as reﬂected in the investigator-rated CAARS:O-SV
and CGI-S scales, and the self-reported CAARS:S-S
and SDS scales. There was also a numerical improve-
ment in quality of life (Q-LES-Q score), although this
was not statistically signiﬁcant.
Furthermore, OROS-MPH was well tolerated dur-
ing the long-term open-label phase, with an adverse-
event proﬁle similar to other studies of MPH in adults
with ADHD (Adler et al. 2011; Bouﬀard et al. 2003;
Kooij et al. 2004; Medori et al. 2008; Spencer et al. 2005)
and no new or unexpected adverse events were re-
ported with long-term exposure. Overall, 12 (7.7%)
subjects had a serious adverse event in the open-label
phase, but none was considered to be related to trial
medication, and there were no deaths in the study.
Cardiovascular and psychiatric adverse events of
special interest occurred in 12% and 4% of subjects,
and were mainly mild or moderate in severity.
Changes from baseline to endpoint in mean blood
pressure, pulse rate and body weight were minimal.
The completion rate in the open-label phase (mean
duration 437 d) was 64%, which is higher than that
observed in a recent open-label study of OROS-MPH
in adults with ADHD (Ro ¨sler et al. 2011), in which 44%
of 129 subjects completed 1 yr of treatment (median
duration 213 d). The higher completion rate and longer
median duration in the present study may relate to the
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Table 5. Eﬃcacy parameters during the double-blind phase
Parametera
(mean¡S.D.)
OROS-MPH
(n=23)
Placebo
(n=22)
CAARS:O-SV total score
Baseline 12.1¡5.3 16.5¡7.5
Endpoint 16.2¡9.4 23.0¡10.4
Change 4.0¡7.6 6.5¡7.8
Treatment diﬀerenceb 2.89
CAARS:O-SV hyperactivity/impulsivity subscale
Baseline 5.3¡2.8 7.0¡3.8
Endpoint 7.8¡4.9 10.5¡5.1
Change 2.5¡3.8 3.4¡4.6
Treatment diﬀerenceb 1.16
CAARS:O-SV inattention subscale
Baseline 6.8¡3.9 9.5¡5.3
Endpoint 8.4¡5.7 12.5¡6.9
Change 1.6¡4.6 3.1¡5.3
Treatment diﬀerenceb 2.14
CAARS-S:SV
Baseline 18.7¡11.1 27.2¡12.5
Endpoint 23.4¡13.9 31.8¡15.6
Change 4.4¡11.9 4.0¡12.0
Treatment diﬀerenceb 2.39
Clinical Global Impression – Severity
Baseline 2.3¡0.7 2.6¡0.9
Endpoint 3.0¡1.3 3.6¡1.4
Change 0.6¡1.1 1.0¡1.2
Q-LES-Q
Baseline 66.2¡9.0 53.2¡12.0
Endpoint 60.8¡15.2 51.1¡13.6
Change –6.5¡11.4 –2.7¡12.4
Treatment diﬀerenceb 2.24
Sheehan Disability Scale
Baseline 9.5¡6.6 13.2¡5.9
Endpoint 11.5¡7.6 15.1¡4.9
Change 2.2¡6.1 1.6¡8.3
Treatment diﬀerenceb 2.30
CAARS, Conners’ Adult ADHD Rating Scale; CAARS:O-SV,
CAARS Observer-rated – Short Version; CAARS:S-SV,
CAARS Self-rated Short Version; Q-LES-Q, Quality of Life
Enjoyment and Satisfaction Questionnaire.
aA reduction in score represents an improvement for all
scales except Q-LES-Q.
bLeast-squares mean diﬀerence between treatment arms.
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Long-term OROS-MPH treatment in adults with ADHD 9fact that this was an extension study in subjects who
had previously completed 12 wk of treatment with
OROS-MPH. In a 1-yr open-label study that only en-
rolled subjects who responded to MPH in a 2-wk pla-
cebo-controlled crossover trial, the completion rate
was even higher (73%) (Wender et al. 2011). The com-
pletion rate in the present study is consistent with
a previous 2-yr study of MPH or dexamphetamine
in adults with ADHD, in which the completion
rates after 6 months and 2 yr were 83% and 50%,
respectively (Bejerot et al. 2010). The completion rate
in the present study compares favourably with
those reported in long-term studies with other treat-
ments in adults with ADHD. In a 1-yr study of
lisdexamfetamine dimesylate, for example, the com-
pletion rate was 55% (Weisler et al. 2009). Interim
analysis of a 3-yr open-label study of atomoxetine re-
ported a completion rate of 43% after mean treatment
duration of 40 wk (maximum 97 wk) (Adler et al.
2005), while in a 1-yr open-label study of adults with
Table 6. Summary of adverse events occurring during the randomized, double-blind
withdrawal phase
Adverse event, n (%) OROS-MPH (n=23) Placebo (n=22)
Any adverse event 7 (30.4) 8 (36.4)
Discontinued because of adverse event 0 0
Serious adverse event 0 1 (4.5)
Treatment-related adverse eventa 3 (13.0) 5 (22.7)
Most common adverse events (i4% of subjects in either arm)
Hypertension 2 (8.7) 0
Irritability 1 (4.3) 1 (4.5)
Nasopharyngitis 1 (4.3) 1 (4.5)
Pyrexia 1 (4.3) 1 (4.5)
Restlessness 1 (4.3) 1 (4.5)
Somnolence 1 (4.3) 1 (4.5)
aAdverse event considered by the investigator to be possibly, probably, or very likely
to be related to study medication.
Table 7. Cardiovascular parameters during the randomized, double-blind with-
drawal phase
Parameter (mean¡S.D.) OROS-MPH (n=23a) Placebo (n=22)
Systolic blood pressure (mmHg)
Baseline 126.7¡11.9 125.7¡13.5
Endpoint 125.5¡13.0 121.5¡13.4
Change –1.5¡10.0 –4.2¡11.6
Diastolic blood pressure (mmHg)
Baseline 78.0¡9.9 78.4¡9.6
Endpoint 80.1¡8.4 73.9¡8.9
Change 1.7¡8.3 –4.5¡8.1
Pulse rate (bpm)
Baseline 79.9¡10.0 76.7¡10.1
Endpoint 77.1¡9.7 71.9¡7.6
Change –2.9¡10.4 –4.8¡9.6
Met clinically relevant criteria, n (%)
Systolic blood pressure >140 mmHg 0 0
Diastolic blood pressure >90 mmHg 2 (9.1) 0
Pulse rate >100 bpm 2 (9.1) 0
an=22 for assessment of clinically relevant criteria at any visit.
10 J. K. Buitelaar et al.ADHD who had responded to a 10-wk course of ato-
moxetine (n=10), only one subject completed the trial
(Johnson et al. 2010). The most common reason for
withdrawal in the present open-label study was an
adverse event, followed by withdrawal of consent. The
most frequent modal doses of OROS-MPH in the
open-label phase were 36 and 54 mg, with a median
dose of 54 mg (range 18–90 mg). Dosing was generally
stable over time.
In the double-blind withdrawal phase, the level of
ADHD symptoms appeared to increase in both treat-
ment arms, with numerically greater increases in
ADHD symptoms (CAARS:O-SV) in the placebo arm
vs. the OROS-MPH arm. Similarly, there was a trend
to better outcomes in terms of functioning and quality
of life with OROS-MPH compared to placebo. The re-
sults on the three pre-speciﬁed outcome measures
(CAARS:O-SV, percentage of subjects with a i1-point
increase in CGI-S score from double-blind baseline,
percentage of subjects with a i2-point increase in
CGI-S from double-blind baseline or discontinuation
due to lack of eﬃcacy) were not statistically signiﬁcant
for the diﬀerence between OROS-MPH and placebo. It
seems likely that this is the result of the relatively
small sample size. Of the 99 subjects who completed
the open-label phase, only 45 consented to participate
in the withdrawal phase, compared with the planned
enrolment of 80. An additional reason for the observed
lack of maintenance of eﬀect may be that subjects were
not required to meet pre-speciﬁed criteria for clinical
response as a condition for randomization. Thus, not
all subjects randomized showed a stable clinical pres-
entation at the end of the open-label phase, usually
a prerequisite for a formal randomized, placebo-
controlled withdrawal study to show maintenance of
therapeutic eﬀect. Further, the observed response
during the open-label phase may have been the result,
in part, of non-treatment-speciﬁc or ‘placebo’ eﬀects.
The possibility of long-term and robust placebo
eﬀects has recently been described in another long-
term eﬃcacy study of OROS-MPH (Biederman et al.
2010). Such robust placebo responses may complicate
and limit the detection of signiﬁcant diﬀerences be-
tween active medication and placebo after random-
ized withdrawal after long-term, open-label treatment.
In addition, it is possible that eﬀective medication for
ADHD symptoms over a longer period of time may
provide patients with the opportunity to develop
better coping and adaptive skills. This may result
in further stabilization of the clinical condition and
continued beneﬁts, even when active medication is
withdrawn (Biederman et al. 2010). It is tempting
to speculate on the possible neural underpinnings of
such an eﬀect, such as adaptive changes in brain
chemistry and synaptic plasticity.
In the double-blind phase, OROS-MPH was well
tolerated, with no clinically important diﬀerences be-
tween the treatment arms and no signal of rebound or
withdrawal reactions in subjects assigned to placebo.
The major contribution of the present study was its
duration, as long-term (i1 yr) data on treatment of
adults with ADHD with MPH are currently limited.
Results should, however, be interpreted with caution,
as patient populations in open-label extension trials
are often ‘selected’ for eﬃcacy and tolerability of
treatment, as they comprise subjects who completed
earlier randomized, controlled studies (Maguire et al.
2008). The patient population in the present study
was, however, similar in terms of its baseline demo-
graphics and disease characteristics to the cohort in
the initial LAMDA double-blind study (Medori et al.
2008). In the double-blind withdrawal phase, the pri-
mary eﬃcacy endpoint failed to show a statistically
signiﬁcant diﬀerence between the treatment arms. A
number of limitations must, however, be taken into
account, such as the small sample size resulting from
attrition during the course of the study; the lack of pre-
speciﬁed criteria for clinical response for the random-
ized withdrawal phase; and the imbalances between
the continued OROS-MPH and placebo arms in terms
of symptom severity at double-blind baseline and
previous OROS-MPH dose during open-label treat-
ment. Overall, these limitations suggest that data from
this randomized withdrawal phase are neither con-
clusive for maintenance of eﬀect after long-term treat-
ment, nor do they call into question the potential
beneﬁt of long-term treatment in adults with ADHD.
In conclusion, the short-term beneﬁts of OROS-
MPH in subjects with ADHD continue during long
term (>1 yr), open-label treatment, with eﬃcacy
and functional outcome parameters showing a small
improvement at endpoint compared to baseline.
Withdrawal of OROS-MPH after long-term treatment
leads to a worsening of subjects’ ADHD symptoms;
further research in a larger cohort is needed to
establish this clearly. Flexibly dosed OROS-MPH
(18–90 mg) was well tolerated by adults with ADHD
during long-term treatment. There was no signal of
rebound or withdrawal in subjects assigned to placebo
during the double-blind phase after randomized
withdrawal.
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